NLS Biotech News

Biotech Business – June 3, 2025

BioNTech and Bristol Myers Squibb enter global strategic partnership

The companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

Biotech Business – June 5, 2025

Alvotech completes SEK 750 million private placement

The transaction attracted interest from institutional investors, with a clear majority allocated to Swedish and other international investors outside of Iceland.

Biotech Business – June 3, 2025

BioNTech and Bristol Myers Squibb enter global strategic partnership

The companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

Biotech Business – June 2, 2025

Bristol Myers Squibb receives European Commission approval for Opdivo

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union.

Biotech Business – May 30, 2025

Alvotech extend partnership with Advanz Pharma

The companies have entered into an agreement to expand their commercial partnership to cover three additional biosimilar candidates.

Clinical trials

Clinical Trials – June 4, 2025

OncoZenge appoints LINK Medical to execute Phase 3 feasibility study

LINK Medical has been engaged to conduct a feasibility study in Europe for the company’s planned Phase 3 study for European approval of BupiZenge.

Clinical Trials – May 26, 2025

Active lymphoma eliminated in two out of three patients in the first cohort of Elicera’s CARMA study

Preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA study with ELC-301 show that two out of three treated patients had no active lymphoma detected on specialized scans, achieving a complete metabolic response.

Clinical Trials – April 13, 2025

Orexo and Abera Bioscience announce positive data

The companies have announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences entered in December 2024. The aim of the collaboration is to develop mucosal vaccines by combining Orexo’s powder-based drug delivery technology AmorphOX with Abera’s […]

Clinical Trials – April 9, 2025

New clinical trial map launched in the EU

A new clinical trial map is now accessible from the public website of the Clinical Trials Information System (CTIS).

Clinical Trials – March 25, 2025

Immunovia provides further positive data from the VERIFI study

Immunovia has announced additional results from the VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially. 

Clinical Trials – March 18, 2025

Oncorena receives FDA approval to initiate studies in the US

The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.

Clinical Trials – March 17, 2025

Anocca to start first in-human trial in advanced pancreatic cancer

The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.

Clinical Trials – February 28, 2025

Evaxion extends phase 2 trial with personalized cancer vaccine

Evaxion Biotech will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the trial from two to three years.

Clinical Trials – February 24, 2025

Medivir presents positive final phase 1b/2a data

Medivir has presented positive, final data from the phase 1b / 2a study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced liver cancer (hepatocellular carcinoma/HCC) at the EASL (European Association for the Study of the Liver) Liver Cancer Summit in Paris, France.

Clinical Trials – January 29, 2025

Herantis reports encouraging pharmacokinetic data

Herantis Pharma has announced an update of the ongoing Phase 1b clinical trial of HER-096.

Profiles in Biotech

Profiles in Biotech – April 23, 2024

Mia Phillipson: Pioneering immunotherapies

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur.

Profiles in Biotech – November 28, 2023

Kristian Tryggvason: Reshaping the cell therapy sector

The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further.

Profiles in Biotech – July 28, 2021

Mathias Uhlén: Driven by curiosity and courage

Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport.

Profiles in Biotech – March 8, 2021

Sara Mangsbo – Scientist and entrepreneur

An academic and an entrepreneur, Dr. Sara Mangsbo, PhD, has found a way to integrate her skills and interests so that they complement and augment her passions.

Profiles in Biotech – January 7, 2021

Evelina Vågesjö: ”I want to see my work go beyond the lab”

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.

Profiles in Biotech – October 8, 2020

Robert Langer: Making a difference in medicine

Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD, turned his chemical engineering skills to medicine, becoming one of the world’s leaders in perfecting effective drug delivery systems.

Profiles in Biotech – June 13, 2018

Britt Meelby Jensen: Accelerating Danish biotech business

She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO. On the contrary, Britt Meelby Jensen enjoys leading, setting ambitious goals and accelerating company growth.

Profiles in Biotech – October 6, 2017

Next-generation biotech entrepreneurs

For young scientists and engineers, a startup can be part of early training and education.

Profiles in Biotech – December 16, 2016

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.

More biotech stories

Biotech Business - June 5, 2025

Alvotech enters collaboration with Dr. Reddy’s

Alvotech and Dr. Reddy’s Laboratories have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.

Biotech Business - May 27, 2025

XOMA Royalty purchases royalty and milestone rights held by BioInvent

XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD 20 million at closing, with a total transaction of up to USD 30 million.

Biotech Business - May 27, 2025

Hansa Biopharma plans restructuring

The planned restructuring would result in an approximately 20% reduction in the current workforce.

Biotech Business - May 27, 2025

Alligator Bioscience announces European orphan drug designation

The European Commission has granted orphan drug designation (ODD) to HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer.

Biotech Business - May 26, 2025

BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU

The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) recommends granting orphan medicinal product designation to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

Biotech Business - May 20, 2025

Umeå-based Omnio raises EUR 4.3 million

“This support allows us to complete our GMP manufacturing process and move toward clinical trials,” says Felipe Velasquez, CEO, Omnio.
Follow NLS news
Follow us on XFollow us on LinkedIn

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.